SCHEMBL4095820

SCHEMBL4095820

CS(=O)(=O)c1nc(-c2ccc(Cl)cc2Cl)c2[nH]cnc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 2/20 0.50
ADORA3 P0DMS8 4/20 0.41
ADORA1 P30542 2/20 0.39
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ADORA2A P29274 1/20 0.38
JAK2 O60674 1/20 0.38
PIK3CA P42336 3/20 0.38
MTOR P42345 1/20 0.38
CYP2C19 P33261 2/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
MCOLN3 Q8TDD5 1/20 0.37
CYP1A2 P05177 1/20 0.35
HSD17B10 Q99714 1/20 0.35
DPP4 P27487 2/20 0.35
PTGS2 P35354 1/20 0.35
DPP8 Q6V1X1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13765774 0.81 DPP4 (0.40) HSP90AB1KDM4EHPGDNPSR1CYP2C19
SCHEMBL4098633 0.76 HSP90AB1 (0.50) HSP90AB1ADORA3ADORA1KDM4EHPGD
SCHEMBL5089221 0.73 MAPT (0.39) HSP90AB1KDM4EHPGDNPSR1JAK2
SCHEMBL14107166 0.73 CRHR1 (0.40) HSP90AB1KDM4EHPGDNPSR1CYP2C19
SCHEMBL5089216 0.71 GSK3B (0.48) KDM4EHPGDNPSR1CYP2C19CYP3A4
SCHEMBL4806164 0.71 CNR1 (0.47) KDM4EHPGDNPSR1PTGS2
SCHEMBL4810834 0.71 PTGS2 (0.42) KDM4EHPGDNPSR1DPP4PTGS2
SCHEMBL4802843 0.70 PTGS2 (0.41) KDM4EHPGDNPSR1DPP4PTGS2
SCHEMBL15444885 0.70 HSD11B1 (0.46) HSP90AB1KDM4EHPGDMAPTDPP4
SCHEMBL4807071 0.69 DPP4 (0.45) KDM4EHPGDNPSR1CYP3A4DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
EP-2004648-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER Vernalis (R&D) Limited (GB) 2008-12-24 EP disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer HSP90AA1, HSP90AB1, HSP90AB2P HSP90AB1 2/4885ADORA3 1010/4885ADORA1 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.